Edmund K Moon
Overview
Explore the profile of Edmund K Moon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singhal S, Rao A, Stadanlick J, Bruns K, Sullivan N, Bermudez A, et al.
Cancer Res
. 2024 Jan;
84(7):1029-1047.
PMID: 38270915
Significance: The elucidation of the conditions and mechanisms by which human FcR+ myeloid effectors mediate cancer cell resistance and killing during antibody treatment could help develop improved strategies for treating...
2.
Jung I, Noguera-Ortega E, Bartoszek R, Collins S, Williams E, Davis M, et al.
Cell Rep Med
. 2023 May;
4(6):101053.
PMID: 37224816
Chimeric antigen receptor (CAR) T cells demonstrate remarkable success in treating hematological malignancies, but their effectiveness in non-hematopoietic cancers remains limited. This study proposes enhancing CAR T cell function and...
3.
Good C, Aznar M, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al.
Cell
. 2021 Dec;
184(25):6081-6100.e26.
PMID: 34861191
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the...
4.
Garcia-Canaveras J, Heo D, Trefely S, Leferovich J, Xu C, Philipson B, et al.
Cells
. 2021 Sep;
10(9).
PMID: 34571983
The metabolic milieu of solid tumors provides a barrier to chimeric antigen receptor (CAR) T-cell therapies. Excessive lactate or hypoxia suppresses T-cell growth, through mechanisms including NADH buildup and the...
5.
Quinn 3rd W, Jiao J, TeSlaa T, Stadanlick J, Wang Z, Wang L, et al.
Cell Rep
. 2020 Dec;
33(11):108500.
PMID: 33326785
Immune cell function is influenced by metabolic conditions. Low-glucose, high-lactate environments, such as the placenta, gastrointestinal tract, and the tumor microenvironment, are immunosuppressive, especially for glycolysis-dependent effector T cells. We...
6.
Predina J, Haas A, Martinez M, OBrien S, Moon E, Woodruff P, et al.
Mol Ther
. 2020 Nov;
29(2):658-670.
PMID: 33160076
Gene-mediated cytotoxic immunotherapy (GMCI) is an immuno-oncology approach involving local delivery of a replication-deficient adenovirus expressing herpes simplex thymidine kinase (AdV-tk) followed by anti-herpetic prodrug activation that promotes immunogenic tumor...
7.
Ma K, Li M, Haas A, Lanfranco A, Moon E, DiBardino D
J Thorac Dis
. 2020 Aug;
12(7):3539-3548.
PMID: 32802433
Background: Airway complications affect roughly 15-20% of lung transplant patients. Airway stents are an attractive therapeutic option; however, no experimental or controlled observational data exists to draw firm conclusions regarding...
8.
Richman S, Wang L, Moon E, Khire U, Albelda S, Milone M
Mol Ther
. 2020 Jul;
28(8):1932.
PMID: 32697941
No abstract available.
9.
Cramer G, Moon E, Cengel K, Busch T
Photochem Photobiol
. 2020 Jun;
96(5):954-961.
PMID: 32573787
Immune checkpoints including PD-1 and CTLA-4 help to regulate the intensity and timeframe of the immune response. Since they become upregulated in cancer and prevent sufficient antitumor immunity, monoclonal antibodies...
10.
Richman S, Wang L, Moon E, Khire U, Albelda S, Milone M
Mol Ther
. 2020 Jun;
28(7):1600-1613.
PMID: 32559430
Chimeric antigen receptor (CAR)-modified T cells are endowed with novel antigen specificity and are most often administered to patients without an engineered mechanism to control the CAR T cells once...